

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

200.1079CON5

APPLICATION NO

10/057,630

APPLICANT

Ronald M. BURCH et al.

FILING DATE

January 25, 2002

GROUP

1639

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A01	4,690,927	09/01/1987	Voss et al.		
	A02	4,844,907	07/04/1989	Elger et al.		
	A03	4,569,937	02/11/1986	Baker et al.		
	A04	5,190,947	03/02/1993	Riess et al.		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

A05	Friedel et al., "Nabumetone- A Reappraisal of its Pharmacology and Therapeutics Use in Rheumatic Diseases," <i>Drugs Vol. 45</i> (1):131-156, (1993)
A06	Eversmeyer et al., "Safety Experience With Nabumetone Versus Diclofenac, Naproxen, Ibuprofen, and Piroxicam in Osteoarthritis and Rheumatoid Arthritis," <i>The American Journal of Medicine, Vol. 95</i> (suppl. 2A) pp.10S-18S, 1993.
A07	Engelhardt et al., "Anti-inflammatory, Analgesic, Antipyretic and Related Properties of Meloxicam, a New Non-Steroidal Anti-inflammatory Agent with Favorable Gastrointestinal Tolerance," <i>Inflamm. Res.</i> 44:423-433 (1995).
A08	Engelhardt, "Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2," <i>Brit. J. Rheumatology</i> 35 (suppl. 1):4-12, 1996.
A09	Distel et al., "Safety of Meloxicam: A Global Analysis of Clinical Trials," <i>Brit. J. Rheumatology</i> 35 (suppl. 1): 68-77, 1996.
A10	Wojtiluewski et al., "A Six Month Double-blind Trial to Compare the Efficacy and Safety of Meloxicam 7.5 mg Daily and Naproxen 750 mg Daily in Patients with Rheumatoid Arthritis," <i>Brit. J. Rheumatology</i> 35 (suppl. 1): 22-28, 1996
A11	Lipani, "Clinical Update of the Relative Safety of Nabumetone in Long-Term Clinical Trials," <i>Inflammopharmacology Vol 3</i> (4) pp. 351-361 (1995)
A12	Siebert et al., "Pharmacological and Biochemical Demonstration of the Role of Cyclooxygenase 2 in Inflammation and Pain," <i>PNAS USA Vol 91</i> pages 12013-12-17 (Dec. 1994)
A13	Richardson et al., "The Clinical Implications of Inhibition of the Inducible Form of Cyclo-oxygenase," <i>Drug Safety Vol. 15</i> (4), pp. 249-260 (Oct. 1996)
A14	Tanaka et al., "Pharmacological Studies of the New Antiinflammatory Agent 3-Formylamino-7-methylsulfonylamino-6-phenoxo-4H-1-benzopyran-4-one," <i>Arzneim-Forsch./Drug res.</i> 42 (II), Nr. 7, pp. 935-944 (1992)
A15	Statement Before the Food and Drug Administration's Arthritis Drugs Advisory Committee on the Nonsteroidal anti-inflammatory Drug Celecoxib. (HRG Publication #1465); December 1, 1998; obtained from http://www.citizen.org/publications/print_release.cfm?ID=6653 on October 28, 2008.
A16	NDA 020938 Approval letter and label April 13, 2000; obtained from http://www.accessdata.fda.gov on October 16, 2008
A17	NDA 20-938 Medical Review, completed August 31, 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008
A18	NDA 20-938 Pharmacology Review(s), completed September 17, 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008
A19	NDA 20-938 Clinical Pharmacology and Biopharmaceutics Review(s), 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008
A20	NDA 20-938 Correspondence, 1998-1999; obtained from http://www.accessdata.fda.gov on October 16, 2008
A21	NDA 20-938 Administrative Documents, 1998; obtained from http://www.accessdata.fda.gov on October 16, 2008
A22	NDA 20-938 Chemistry Review(s), 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008
A23	NDA 20-938 Microbiology Review(s) 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008

EXAMINER

/Christopher Gross/ (01/21/2011)

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CG/

FORM PTO-1449 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. 200.1079CON5	APPLICATION NO 10/057,630
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Ronald M. BURCH et al.	
		FILING DATE January 25, 2002	GROUP 1639

OTHER REFERENCES <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>	
A24	NDA 20-938 Statistical Review(s) 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008
A25	Therapeutics Initiative, February 1995
A26	Therapeutics Initiative, January 1997
A27	Therapeutics Initiative, January/February 2001
A28	Prescribing Points, volume 8.4, June 1999
A29	Lichtblau, L. et al., "Pharmacologic management of cancer pain in rural Minnesota," <i>J Pain Symptom Manage</i> , Vol. 12, No. 5, p. 283-9, 1996.
A30	Wollheim, F.A., "Current pharmacological treatment of osteoarthritis," <i>Drugs</i> , Vol. 52, Suppl. 3, p. 27-38, 1996.
A31	Furst, D.E., "Meloxicam: selective COX-2 inhibition in clinical practice," <i>Semin Arthritis Rheum</i> , Vol. 26, No. 6, Suppl. 1, pp. 21-7, 1997.
A32	Capasso, Anna et al. "Arachidonic acid and its metabolites are involved in the expression of morphine dependence in guinea-pig isolated ileum" <i>European Journal of Pharmacology</i> Vol. 330 (1997), pp. 199-204

EXAMINER	/Christopher Gross/ (01/21/2011)	DATE CONSIDERED
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CG/